Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Aspira Women’s Health ( (AWH) ) is now available.
Aspira Women’s Health announced the immediate departure of CEO Nicole Sandford, who will remain as a consultant, with President Dr. Sandra Milligan stepping in as interim CEO while a search for a permanent successor is conducted. Sandford’s leadership saw significant milestones including the launch of OvaWatch and a substantial grant for endometriosis research, positioning the company for future growth. The transition is expected to be smooth with Milligan’s deep understanding of the company’s technology and strategies.
More about Aspira Women’s Health
Aspira Women’s Health Inc. is a bio-analytical based company dedicated to developing noninvasive, AI-powered diagnostic tests for gynecologic diseases. The company offers OvaWatch and Ova1Plus as part of its OvaSuite portfolio, which provides comprehensive blood tests for assessing ovarian cancer risk in women with adnexal masses. Aspira is also advancing its pipeline to include non-invasive diagnostics for endometriosis, aiming to enhance the sensitivity and specificity of its tests by combining microRNA and protein biomarkers with patient data.
YTD Price Performance: -81.64%
Average Trading Volume: 93,017
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.5M
For an in-depth examination of AWH stock, go to TipRanks’ Stock Analysis page.
